Please login to the form below

Not currently logged in
Email:
Password:

Evrysdi

This page shows the latest Evrysdi news and features for those working in and with pharma, biotech and healthcare.

Genentech’s Evrysdi gets extended FDA approval for spinal muscular atrophy

Genentech’s Evrysdi gets extended FDA approval for spinal muscular atrophy

The study showed that after one year of treatment with Evrysdi 100% of babies with two or three copies of the SMN2 gene were able to sit up. ... Evrysdi is approved in 81 countries worldwide and is under review in a further 27 countries.

Latest news

More from news
Approximately 4 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....